Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Net Income (2020 - 2025)

Historic Net Income for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to -$12.4 million.

  • Maxcyte's Net Income fell 743.27% to -$12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.6 million, marking a year-over-year decrease of 2768.92%. This contributed to the annual value of -$41.1 million for FY2024, which is 825.88% down from last year.
  • Per Maxcyte's latest filing, its Net Income stood at -$12.4 million for Q3 2025, which was down 743.27% from -$12.4 million recorded in Q2 2025.
  • Maxcyte's 5-year Net Income high stood at -$2.7 million for Q3 2021, and its period low was -$12.4 million during Q3 2025.
  • Its 5-year average for Net Income is -$8.2 million, with a median of -$9.4 million in 2024.
  • In the last 5 years, Maxcyte's Net Income skyrocketed by 4275.92% in 2022 and then tumbled by 16754.85% in 2023.
  • Maxcyte's Net Income (Quarter) stood at -$4.9 million in 2021, then increased by 1.33% to -$4.8 million in 2022, then dropped by 9.74% to -$5.3 million in 2023, then crashed by 100.78% to -$10.6 million in 2024, then fell by 17.17% to -$12.4 million in 2025.
  • Its Net Income stands at -$12.4 million for Q3 2025, versus -$12.4 million for Q2 2025 and -$10.3 million for Q1 2025.